表紙
市場調查報告書

異位性皮膚炎:開發平台分析

Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 232797
出版日期 內容資訊 英文 639 Pages
訂單完成後即時交付
價格
異位性皮膚炎:開發平台分析 Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 639 Pages
簡介

異位性皮膚炎是皮膚變癢的發炎,也有慢性的症狀拖長,伴隨氣喘和花粉症。 症侯有紅色到帶茶色的灰色斑點,發癢,尤其是夜間變得厲害。有小小隆起的疙瘩,抓的話會有體液流出變成瘡痂,肥厚性的鱗狀皮膚,抓的話潰爛變敏感的皮膚等。

本報告提供異位性皮膚炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍
  • 異位性皮膚炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Abeome Corporation
  • Accolade Pharmaceuticals, LLC
  • AlbireoPharma
  • Almirall, S.A.
  • Amgen Inc.
  • Amorepacific Corporation
  • Anacor Pharmaceuticals, Inc.
  • AnaMar AB
  • AnaptysBio, Inc.
  • AnGes MG, Inc.
  • Aquinox Pharmaceuticals Inc.
  • arGEN-X BV
  • Blueberry Therapeutics Ltd
  • Brickell Biotech, Inc.
  • Celgene Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • 中外製藥
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Dr. August Wolff GmbH & Co. KG Arzneimittle
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Ferrer Internacional, S.A.
  • Han Wha Pharma Co., Ltd.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Immune Pharmaceuticals Inc.
  • Inflamalps SA
  • 日本煙草產業
  • Johnson & Johnson
  • Kineta, Inc.
  • LegoChem Biosciences, Inc
  • LEO Pharma A/S
  • Madam Therapeutics B.V.
  • MedImmune, LLC
  • NeoPharm Co., Ltd.
  • Novan, Inc.
  • Novartis AG
  • Orbis Biosciences, Inc.
  • 大塚集團
  • Oxagen Limited
  • Pfizer Inc.
  • Pharis Biotec GmbH
  • Pharmedartis GmbH
  • Provectus Biopharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Signum Dermalogix, Inc
  • Spherium Biomed S.L.
  • sterna biologicals Gmbh & Co KG
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • SWITCH Biotech LLC
  • 武田藥品工業
  • Thesan Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Vicore Pharma AB
  • Vitae Pharmaceuticals, Inc.
  • VivaCell Biotechnology Espana S.L.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • A-3914
  • A-5425
  • AKP-11
  • ALX-101
  • AM-1030
  • AN-4161
  • ANB-020
  • apremilast
  • 異位性皮膚炎用Galectin-3抑制適體
  • AQX-1125
  • ARGX-112
  • ARN-077
  • baricitinib
  • BB-2702
  • BBI-2000
  • BBI-5000
  • bertilimumab
  • 異位性皮膚炎、皮膚炎用生技藥品
  • C-21
  • CBP-174
  • CBP-201
  • CCX-6239
  • CDE-001
  • Cis-Urocanic Acid
  • CNTO-7160
  • kobamamido
  • crisaborole
  • CT-101
  • CT-1x1
  • CT-1x2
  • CT-1x3
  • CT-327
  • CT-340
  • Cyclosporine
  • dalazatide
  • DMT-210
  • DRM-02
  • 異位性皮膚炎治療藥
  • 異位性皮膚炎用 TNFR-1拮抗劑
  • deyupirumabu
  • FB-825
  • fevipiprant
  • FIB-116
  • Furestem-AD
  • GBR-830
  • Histimex
  • HS-378
  • JTE-052
  • KPI-150
  • LCB-030110
  • lebrikizumab
  • LEKTI-6
  • LEO-32731
  • LEO-39652
  • mepolizumab
  • MLR-1130
  • mometasone furoate
  • 氣喘、線維症、異位性皮膚炎用 IL-25抑制單株抗體
  • 異位性皮膚炎用 IL-4/IL-13抑制單株抗體
  • 發炎性用腸道疾病、 異位性皮膚炎、大腸癌 Th22細胞/IL-22途徑標的單株抗體
  • N-oleoylethanolamine
  • nemolizumab
  • NPH-12
  • OC-000459
  • OC-2417
  • octenidine hydrochloride
  • OLX-103
  • omiganan pentahydrochloride
  • OPA-15406
  • P-10
  • PAC-14028
  • PDI-192
  • 異位性皮膚炎用 CX3CR1拮抗肽
  • 異位性皮膚炎用 TNFR-1拮抗肽
  • PH-10
  • PL-601
  • PMA-101R
  • PMA-201
  • PMA-411R
  • prednisone
  • PZ-235
  • Q-301
  • Qi-507
  • roflumilast
  • RTU-1096
  • RVT-501
  • S-414114
  • SB-011
  • SB-414
  • SIG-1311
  • SIG-1322
  • 異位性皮膚炎用 S1PR1調整藥
  • 異位性皮膚炎用小分子
  • SP-14019
  • SUN-0597
  • SWT-01113
  • SWT-05141
  • 免疫學、皮膚疾病、遺傳性疾病用激肽釋放酶抑制合成肽
  • tacrolimus
  • tezepelumab
  • tofacitinib
  • tralokinumab
  • ustekinumab
  • VTP-38543
  • WBI-1001
  • WOL-071007
  • XmAb-7195
  • YJC-10592
  • Zafi-1
  • ZPL-3893787
  • ZPL-5212372

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11983IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H1 2020, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 50, 24, 4, 54, 23 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 8 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Atopic Dermatitis (Atopic Eczema) - Overview
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
  • Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Drug Profiles
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products
  • Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..8), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects, H1 2020 (Contd..9), H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H1 2020
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020